Increased Risk of Second Primary Malignancy in Pediatric and Young Adult Patients Treated with Radioactive Iodine for Differentiated Thyroid Cancer

Overview

Journal Thyroid

Date 2015 Apr 9

PMID 25851829

Citations 27

Authors

Jennifer L Marti

Kunal S Jain

Luc G T Morris

Affiliations

Soon will be listed here.

Abstract

Introduction: The long-term sequelae of radioactive iodine (RAI) for differentiated thyroid cancer (DTC) in pediatric and young adult patients are not well-defined. Epidemiologic analyses of second primary malignancy (SPM) risk have only been performed in the adult population. Existing data are limited to case series with limited follow-up. The objective of this study was to analyze the elevated risk of SPM attributable to RAI in young patients treated for DTC.

Methods: Population-based analysis of 3850 pediatric and young adult patients (<25 years old) undergoing treatment with surgery with/without RAI for DTC, followed in the Surveillance, Epidemiology, and End Results cancer registry (1973-2008), equating to 54,727 person-years at risk (PYR). The excess risk of SPM was calculated relative to a reference population and expressed as standardized incidence ratio (SIR) and excess absolute risk (EAR) per 10,000 PYR. Excess risk was compared in RAI-treated and non-RAI-treated patients.

Results: A total of 1571 patients (40%) received RAI. The percentage of patients treated with RAI increased over time, from 4% in 1973 to 62% in 2008 (p<0.001). Among patients who received RAI, 26 SPMs were observed, and 18.3 were expected. The relative risk of SPM at any site was significantly elevated (SIR=1.42), corresponding to 4.4 excess cases per 10,000 PYR. SPM risk was not elevated in the non-RAI-treated cohort (SIR=1.01, EAR=0). Patients treated with RAI were at dramatically elevated risk for development of a salivary malignancy (SIR=34.1), corresponding to 1.7 excess cases per 10,000 PYR. The risk of leukemia in RAI-treated patients was elevated (SIR=4.0, EAR=0.9) but did not reach statistical significance. There was no elevated risk of salivary cancer or leukemia in the non-RAI-treated cohort.

Conclusions: Pediatric and young adult patients who receive RAI for DTC experience an elevated risk of SPM, mainly salivary gland cancer. These risks appear to be only slightly higher than in adult patients. Over a decade, approximately 1 in 227 RAI-treated patients will develop an SPM, and 1 in 588 RAI-treated patients will develop a salivary cancer, attributable to RAI. Because the expected survival time for young DTC patients is long, it is critical to weigh the benefits of RAI carefully against the small, but real, increase in SPM risk.

Citing Articles

The Impact of Radioactive Iodine on Outcomes Among Pediatric and Adolescent Thyroid Cancer Patients: A SEER Database Analysis.

Persons E, Hussein M, Herrera M, Pinion D, Webster A, Pineda E Cancers (Basel). 2025; 17(1.

PMID: 39796737 PMC: 11720182. DOI: 10.3390/cancers17010107.

Radiation Implication in Pediatric Second Primary Thyroid Malignancy (SPTM) Cumulative Incidence and Mortality in the United States: Large Cohort Evidence.

Holmes Jr L, Simon-Plumb C, Ziegler R, Ogundele B, Holmes M, Dabney K Cancers (Basel). 2024; 16(21).

PMID: 39518075 PMC: 11544766. DOI: 10.3390/cancers16213637.

Advances in the selection and timing of postoperative radioiodine treatment in patients with differentiated thyroid carcinoma.

Dai X, Ren X, Zhang J, Zheng Y, Wang Z, Cheng G Ann Nucl Med. 2024; 38(9):688-699.

PMID: 39044048 DOI: 10.1007/s12149-024-01963-z.

Incidentally Detected Metachronous Malignancy in Patients of Papillary Carcinoma of Thyroid Posthigh-Dose Radioiodine Therapy.

Mishra A, Singh V, Khandelwal Y, Smitha A, Kavali D, Barai S Indian J Nucl Med. 2023; 38(3):264-269.

PMID: 38046960 PMC: 10693376. DOI: 10.4103/ijnm.ijnm_188_22.

Primary presentation and clinical course of pediatric and adolescent patients with differentiated thyroid carcinoma after radioiodine therapy.

Burgard C, Zacherl M, Todica A, Hornung J, Grawe F, Pekrul I Front Oncol. 2023; 13:1237472.

PMID: 37849815 PMC: 10577432. DOI: 10.3389/fonc.2023.1237472.

References

Welch Dinauer C, Tuttle R, Robie D, McClellan D, Svec R, Adair C . Clinical features associated with metastasis and recurrence of differentiated thyroid cancer in children, adolescents and young adults. Clin Endocrinol (Oxf). 1999; 49(5):619-28. DOI: 10.1046/j.1365-2265.1998.00584.x. View

Clegg L, Feuer E, Midthune D, Fay M, Hankey B . Impact of reporting delay and reporting error on cancer incidence rates and trends. J Natl Cancer Inst. 2002; 94(20):1537-45. DOI: 10.1093/jnci/94.20.1537. View

Clegg L, Gail M, Feuer E . Estimating the variance of disease-prevalence estimates from population-based registries. Biometrics. 2002; 58(3):684-8. DOI: 10.1111/j.0006-341x.2002.00684.x. View

Chodick G, Ronckers C, Shalev V, Ron E . Excess lifetime cancer mortality risk attributable to radiation exposure from computed tomography examinations in children. Isr Med Assoc J. 2007; 9(8):584-7. View

Iyer N, Morris L, Tuttle R, Shaha A, Ganly I . Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer. 2011; 117(19):4439-46. PMC: 3155861. DOI: 10.1002/cncr.26070. View

Brenner D, Hall E . Computed tomography--an increasing source of radiation exposure. N Engl J Med. 2007; 357(22):2277-84. DOI: 10.1056/NEJMra072149. View

Chow S, Law S, Mendenhall W, Au S, Yau S, Mang O . Differentiated thyroid carcinoma in childhood and adolescence-clinical course and role of radioiodine. Pediatr Blood Cancer. 2004; 42(2):176-83. DOI: 10.1002/pbc.10410. View

Schoenberg B, Myers M . Statistical methods for studying multiple primary malignant neoplasms. Cancer. 1977; 40(4 Suppl):1892-8. DOI: 10.1002/1097-0142(197710)40:4+<1892::aid-cncr2820400820>3.0.co;2-h. View

Brenner D, Elliston C, Hall E, BERDON W . Estimated risks of radiation-induced fatal cancer from pediatric CT. AJR Am J Roentgenol. 2001; 176(2):289-96. DOI: 10.2214/ajr.176.2.1760289. View

10.

Cooper D, Doherty G, Haugen B, Hauger B, Kloos R, Lee S . Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009; 19(11):1167-214. DOI: 10.1089/thy.2009.0110. View

11.

Newman K, Black T, Heller G, Azizkhan R, Holcomb 3rd G, Sklar C . Differentiated thyroid cancer: determinants of disease progression in patients <21 years of age at diagnosis: a report from the Surgical Discipline Committee of the Children's Cancer Group. Ann Surg. 1998; 227(4):533-41. PMC: 1191309. DOI: 10.1097/00000658-199804000-00014. View

12.

Dottorini M, Vignati A, Mazzucchelli L, Lomuscio G, Colombo L . Differentiated thyroid carcinoma in children and adolescents: a 37-year experience in 85 patients. J Nucl Med. 1997; 38(5):669-75. View

13.

Demidchik Y, Demidchik E, Reiners C, Biko J, Mine M, Saenko V . Comprehensive clinical assessment of 740 cases of surgically treated thyroid cancer in children of Belarus. Ann Surg. 2006; 243(4):525-32. PMC: 1448966. DOI: 10.1097/01.sla.0000205977.74806.0b. View

14.

Clegg L, Reichman M, Hankey B, Miller B, Lin Y, Johnson N . Quality of race, Hispanic ethnicity, and immigrant status in population-based cancer registry data: implications for health disparity studies. Cancer Causes Control. 2007; 18(2):177-87. DOI: 10.1007/s10552-006-0089-4. View

15.

Rubino C, De Vathaire F, Dottorini M, Hall P, Schvartz C, Couette J . Second primary malignancies in thyroid cancer patients. Br J Cancer. 2003; 89(9):1638-44. PMC: 2394426. DOI: 10.1038/sj.bjc.6601319. View

16.

ZIPPIN C, Lum D, Hankey B . Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute. Cancer. 1995; 76(11):2343-50. DOI: 10.1002/1097-0142(19951201)76:11<2343::aid-cncr2820761124>3.0.co;2-#. View

17.

Enomoto Y, Enomoto K, Uchino S, Shibuya H, Watanabe S, Noguchi S . Clinical features, treatment, and long-term outcome of papillary thyroid cancer in children and adolescents without radiation exposure. World J Surg. 2012; 36(6):1241-6. DOI: 10.1007/s00268-012-1558-4. View

18.

Brown A, Chen J, Hitchcock Y, Szabo A, Shrieve D, Tward J . The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab. 2007; 93(2):504-15. DOI: 10.1210/jc.2007-1154. View

19.

Sawka A, Thabane L, Parlea L, Ibrahim-Zada I, Tsang R, Brierley J . Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid. 2009; 19(5):451-7. DOI: 10.1089/thy.2008.0392. View

20.

Hogan A, Zhuge Y, Perez E, Koniaris L, Lew J, Sola J . Pediatric thyroid carcinoma: incidence and outcomes in 1753 patients. J Surg Res. 2009; 156(1):167-72. DOI: 10.1016/j.jss.2009.03.098. View